| Title |
Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
|
|---|---|
| Published in |
Journal of Asthma and Allergy, June 2018
|
| DOI | 10.2147/jaa.s156049 |
| Pubmed ID | |
| Authors |
Moshe Ashkenazi, Saray Sity, Ifat Sarouk, Bat El Bar Aluma, Adi Dagan, Yael Bezalel, Lea Bentur, Kris De Boeck, Ori Efrati |
| Abstract |
Allergic bronchopulmonary aspergillosis (ABPA) is a condition characterized by a Th2 response, serum eosinophilia, and increased total serum IgE to Aspergillus fumigatus. ABPA occurs in cystic fibrosis (CF) and asthma. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Previous studies reported borderline results when treating ABPA with omalizumab. A retrospective study to investigate the efficacy of omalizumab in the treatment of ABPA in CF patients was conducted at 3 CF centers in Israel and Belgium. Data were obtained from the digital archive. We measured 4 outcome parameters: forced expiratory volume in 1 second, body mass index, pulmonary exacerbations, and steroid sparing. The database was composed on the records of 9 patients. None of the outcome parameters showed any improvement. A favorable outcome was observed in patients with higher levels of posttreatment total IgE than those with lower levels. CF-related diabetes and male gender showed trends for poorer outcomes. No benefits were detected on treating ABPA in CF with omlaizumb. Monitoring the total IgE was not helpful. A prospective randomized double-blind study is needed. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Turkey | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 65 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 12 | 18% |
| Student > Bachelor | 11 | 17% |
| Researcher | 10 | 15% |
| Student > Master | 9 | 14% |
| Student > Ph. D. Student | 5 | 8% |
| Other | 10 | 15% |
| Unknown | 8 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 51% |
| Biochemistry, Genetics and Molecular Biology | 7 | 11% |
| Agricultural and Biological Sciences | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Immunology and Microbiology | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 11 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 July 2018.
All research outputs
#13,930,202
of 23,094,276 outputs
Outputs from Journal of Asthma and Allergy
#265
of 463 outputs
Outputs of similar age
#176,593
of 330,325 outputs
Outputs of similar age from Journal of Asthma and Allergy
#6
of 6 outputs
Altmetric has tracked 23,094,276 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 463 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,325 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.